Mycovia Pharms Drug Patent Portfolio
Mycovia Pharms owns 1 orange book drug protected by 5 US patents Given below is the list of Mycovia Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10414751 | Antifungal compounds and processes for making | 17 Mar, 2036 | Active |
| US9840492 | Antifungal compounds and processes for making | 17 Mar, 2036 | Active |
| US11247981 | Metalloenzyme inhibitor compounds | 09 May, 2033 | Active |
| US8236962 | Metalloenzyme inhibitor compounds | 22 Apr, 2031 | Active |
| US8754227 | Metalloenzyme inhibitor compounds | 22 Apr, 2031 | Active |
Latest Legal Activities on Mycovia Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mycovia Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent eCertificate of Correction | 05 Mar, 2024 | US11247981 |
|
Email Notification
Critical
| 05 Mar, 2024 | US11247981 |
| Patent eCofC Notification | 05 Mar, 2024 | US11247981 |
| Mail Patent eCofC Notification | 05 Mar, 2024 | US11247981 |
| Post Issue Communication - Certificate of Correction | 15 Feb, 2024 | US11247981 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8236962 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Mar, 2023 | US10414751 |
| Initial letter Re: PTE Application to regulating agency | 08 Jul, 2022 | US8236962 |
| Post Issue Communication - Certificate of Correction | 12 May, 2022 | US11247981 |
|
Recordation of Patent Grant Mailed
Critical
| 15 Feb, 2022 | US11247981 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 15 Feb, 2022 | US11247981 |
|
Email Notification
Critical
| 27 Jan, 2022 | US11247981 |
|
Issue Notification Mailed
Critical
| 26 Jan, 2022 | US11247981 |
| Dispatch to FDC | 06 Jan, 2022 | US11247981 |
|
Application Is Considered Ready for Issue
Critical
| 06 Jan, 2022 | US11247981 |
Mycovia Pharms's Family Patents
Mycovia Pharms drugs have patent protection in a total of 22 countries. It's US patent count contributes only to 24.2% of its total global patent coverage. Click
below to unlock the full patent family tree.
Mycovia Pharms Drug List
Given below is the complete list of Mycovia Pharms's drugs and the patents protecting them.
1. Vivjoa
Vivjoa is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10414751 | Antifungal compounds and processes for making |
17 Mar, 2036
(11 years from now)
| Active |
| US9840492 | Antifungal compounds and processes for making |
17 Mar, 2036
(11 years from now)
| Active |
| US11247981 | Metalloenzyme inhibitor compounds |
09 May, 2033
(8 years from now)
| Active |
| US8236962 | Metalloenzyme inhibitor compounds |
22 Apr, 2031
(6 years from now)
| Active |
| US8754227 | Metalloenzyme inhibitor compounds |
22 Apr, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vivjoa's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List